Healthcare Services Australia

Australia Diabetes Prevention Programs Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

Australia Diabetes Prevention Programs Market Industry Trends and Forecast to 2034: Segmented by (Delivery, Payer, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Australia · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $41.4 Mn Placeholder estimate
Estimate 2025 $46.5 Mn 1.2% of the global market
Projected 2034 $132.2 Mn 184.1% Adds $85.7 Mn over 9 forecast years
CAGR 2025–2034 12.3% Faster than 66% of 107 Healthcare Services markets here
Key players 5
  • Australia is 1.22% of the global market.
  • In APAC, the largest is China at $353.8 Mn.
  • Fastest growing: India at 13.6% a year.
  • Australia ranks 4th of 10 by size in APAC.

Market size projection

Australia

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$85.7 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Diabetes Prevention Programs Market market size by year, Australia
YearMarket sizeChange that yearSince 2025
2024 (estimate) $41.4 Mn — —
2025 (base) $46.5 Mn +$5.1 Mn —
2026 (forecast) $52.3 Mn +$5.7 Mn +12.3%
2027 (forecast) $58.7 Mn +$6.4 Mn +26.1%
2028 (forecast) $65.9 Mn +$7.2 Mn +41.6%
2029 (forecast) $74.0 Mn +$8.1 Mn +59%
2030 (forecast) $83.1 Mn +$9.1 Mn +78.6%
2031 (forecast) $93.3 Mn +$10.2 Mn +100.6%
2032 (forecast) $104.8 Mn +$11.5 Mn +125.2%
2033 (forecast) $117.7 Mn +$12.9 Mn +153%
2034 (forecast) $132.2 Mn +$14.5 Mn +184.1%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Australia Diabetes Prevention Programs Market Analysis at a glance
Market size, 2025$46.5 Mn placeholder estimate
Forecast, 2034$132.2 Mn placeholder estimate
Growth (CAGR), 2025–203412.3% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsDelivery, payer and end user (see all)
Key playersOmada Health, Virta Health, Lark Health, WW International, Livongo Health (now part of Teladoc Health) (see all)
Active clinical trials1 in AustraliaSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Australia. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Australia Diabetes Prevention Programs Market Analysis Executive Summary

Diabetes prevention programs help people with prediabetes lower their risk of type 2 diabetes through coaching on diet, activity and weight.

Key segments of the diabetes Prevention Programs market include delivery (In-Person Programs, Digital Programs and Hybrid Programs) and payer (Employers, Health Plans and Government).

Bar chart: Australia Diabetes Prevention Programs market size, 2024–2034, placeholder estimates. $41.4 Mn in 2024, $46.5 Mn in 2025 and $132.2 Mn in 2034, 12.3% CAGR.
Australia Diabetes Prevention Programs market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Australia Diabetes Prevention Programs Market Dynamics

Market Growth Drivers

Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the diabetes Prevention Programs market. Wider insurance coverage and more doctors trained in obesity care are adding to demand.

Opportunity

Oral formulations, combination therapies and use in heart, kidney and liver disease open new growth paths for the diabetes Prevention Programs market, especially in fast-growing emerging economies.

Market Restraints

High treatment prices, limited reimbursement, supply shortages and side effects that lead some patients to stop treatment hold back the diabetes Prevention Programs market. Long-term safety data and lifestyle support are still needed for many patients.

Competitive Landscape for Diabetes Prevention Programs Market in Australia

The diabetes Prevention Programs market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Diabetes Prevention Programs Market in Australia

Diabetes Prevention Programs in Australia: payment and research

Medicare pays for public hospital care and many doctor visits, and the Pharmaceutical Benefits Scheme (PBS) subsidises listed medicines.⁠[1] ClinicalTrials.gov lists 1 study on Diabetes Prevention Programs that is recruiting, active or about to start in Australia.⁠[2] Diabetes (adults): 8.1% of adults in 2022, the latest WHO figure for Australia.⁠[3]

[1] Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.

[2] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Australia. Retrieved 12 Nov 2026.

[3] WHO Global Health Observatory, Diabetes (adults, WHO) (% of adults). Retrieved 15 Nov 2026.

Policy changes and Reimbursement scenario

Licensing, quality standards and payment models from public and private payers shape how diabetes Prevention Programs services are delivered and paid for in Australia. Government health programs and insurance coverage are key to access.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Diabetes Prevention Programs right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory, World Bank. Fetched 15 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Diabetes Prevention Programs in context

Australia compared

  • Diabetes (adults, WHO): 8.1% of adults (2022). World: 14.1% of adults (2022). 14th highest of the 15 countries we cover in APAC.[1]
  • Health spending per person: 6,980 US$ per person (2023). World: 1,317 US$ per person (2023). Highest of the 15 countries we cover in APAC.[2]
  • Doctors: 4.09 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). Highest of the 15 countries we cover in APAC.[3]

[1] WHO Global Health Observatory, Diabetes (adults, WHO) (% of adults). Retrieved 14 Nov 2026.

[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 15 Nov 2026.

[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 14 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Diabetes Prevention Programs market in Australia?
Placeholder estimate: about $46.5 Mn in 2025, rising to about $132.2 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Diabetes Prevention Programs market in Australia growing?
Placeholder estimate: about 12.3% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Diabetes Prevention Programs market report cover?
The report splits the market by delivery (In-Person Programs, Digital Programs, Hybrid Programs), payer (Employers, Health Plans, Government) and end user (Hospitals, Clinics, Home Care, Corporate and Payer Clients).
Who are the key players in the Diabetes Prevention Programs market?
Key players include Omada Health, Virta Health, Lark Health, WW International and Livongo Health (now part of Teladoc Health).
What is driving the Diabetes Prevention Programs market?
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the diabetes Prevention Programs market.
How is healthcare paid for in Australia?
Medicare pays for public hospital care and many doctor visits, and the Pharmaceutical Benefits Scheme (PBS) subsidises listed medicines. Source: Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.
How many clinical trials on Diabetes Prevention Programs are running in Australia?
1 study is recruiting, active or about to start in Australia, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Australia. Retrieved 12 Nov 2026.
What does WHO report for Australia?
Diabetes (adults): 8.1% of adults in 2022, the latest WHO figure. Source: WHO Global Health Observatory, Diabetes (adults, WHO) (% of adults). Retrieved 15 Nov 2026.
How many people in Australia are 65 or older?
18.1% of people were 65 or older in 2025. Source: World Bank Open Data, Population ages 65 and above (% of total population), from UN population estimates. Retrieved 15 Nov 2026.
How much research is published on Diabetes Prevention Programs?
PubMed lists 134 papers on Diabetes Prevention Programs added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Healthcare Services reports in Australia

See all

Related on obesity and diabetes

See the topic